Spine BioPharma's Phase III MODEL trial assessing SB-01 for people with CLBP associated with DDD failed to achieve its primary goal.

Anavex's blarcasemine met its primary endpoints, improving cognition and function over a four year period in early-stage Alzheimer’s patients.

Eli Lilly’s trial evaluating Mounjaro in reducing cardiovascular risk met its endpoint, though missed analyst expectations.

Eli Lilly's Jaypirca met its non-inferiority primary endpoint, trumping Imbruvica in patient overall response rate (ORR).

Lantern Pharma has completed targeted enrolment for its multi-centre Phase II HARMONIC trial of a disulfide small molecule, LP-300.

Industry experts have provided insight into how oncology clinical trials can be designed for success from the outset and rendered as patient-centric as possible.

AbbVie has reported topline outcomes from the first of two trials of the Phase III UP-AA programme, assessing Rinvoq (upadacitinib).

Roche’s Alzheimer’s disease therapy has continued to show benefit for patients after 28 weeks in a long-term extension study.

Cognition Therapeutics’ therapy showed up to a 129% slowing of cognitive decline in mild Alzheimer’s disease patients.

Recognify Life Sciences has reported that its Phase IIb trial of inidascamine to treat CIAS failed to achieve its primary goal.

Windward Bio has launched the Phase II POLARIS trial of the recombinant, fully human monoclonal antibody, WIN378, in individuals with asthma.

Eli Lilly’s Kisunla and Biogen/Eisai’s Leqembi can both continue to slow Alzheimer's cognitive decline after over three years of treatment.